A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
← catalyst calendarNCT07783802 · readout ≤ 278 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
120estimated
Sites
47
Countries
Argentina, Japan, Puerto Rico +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-25
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Sep 2026 | estimated | When the study began enrolling |
| Primary completion | May 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Atherosclerosis
- Cardiovascular Disease
- Obesity
- Hypertension
- Diabetes Mellitus, Type 2
- Renal Insufficiency, Chronic
Interventions
- Drug: Clazakizumab — also filed as LY5724886
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent Change from Baseline in hsCRP
measured Baseline, Week 12
Related
LLY · their whole pipeline · Obesity readouts · Congress trades in LLY · Executive-branch trades in LLY
LLY's other studiesmost recently updated first
- A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults Phase 3 · Recruiting
- A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) Phase 2 · Recruiting
- A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants Phase 1 · Completed
- A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis Phase 3 · Recruiting
- A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON) Phase 3 · Recruiting
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed